Miller Value Partners LLC Takes $4 Million Position in Bristol Myers Squibb Company $BMY

Miller Value Partners LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 69,500 shares of the biopharmaceutical company’s stock, valued at approximately $4,005,000.

Other hedge funds have also added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after purchasing an additional 172 shares in the last quarter. KCM Investment Advisors LLC increased its stake in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 174 shares during the last quarter. Sandy Cove Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 4.7% during the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 176 shares in the last quarter. Investment Research Partners LLC lifted its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 179 shares during the last quarter. Finally, ESG Planning DBA Harper Investing lifted its position in shares of Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on BMY shares. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating for the company. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued an “overweight” rating on the stock. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada increased their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Stock Up 0.9%

NYSE:BMY opened at $67.86 on Wednesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company has a market cap of $138.62 billion, a PE ratio of 14.95, a P/E/G ratio of 0.17 and a beta of 0.22. The firm’s 50 day simple moving average is $61.01 and its 200 day simple moving average is $59.54.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.